We became hostages to pharmaceutical lobbies: Ameer Shahul

Published on April 10, 2026

“We became hostages to pharmaceutical lobbies,” says Ameer Shahul as he reflects on the complex landscape of immunization in India. In his recent discourse, Shahul traces the history and evolution of vaccination in the country, shedding light on the unsung heroes of immunology and emphasizing the crucial role played initiatives in fostering a robust vaccine ecosystem.

The narrative of immunization in India is rich with groundbreaking discoveries and innovative research, much of which often goes unrecognized. Shahul highlights the contributions of forgotten scientists, whose pioneering work laid the foundation for modern vaccination efforts. From the early days of vaccine development to the challenges faced in scaling production, these individuals have played a vital role in safeguarding public health.

As the global demand for vaccines has surged, particularly in the wake of the COVID-19 pandemic, Shahul expresses concern over the increasing influence of pharmaceutical lobbies. He contends that the focus on profit-driven motives has overshadowed the collective goal of ensuring equitable access to vaccines for all. “We must not allow profit to dictate public health,” he asserts, urging for a reassessment of priorities in vaccine distribution.

Shahul points to the pivotal role of the public sector in building a sustainable vaccine ecosystem. He argues that government investment in research and development, along with support for local manufacturers, is essential for enhancing India’s self-reliance in vaccine production. The success of India’s vaccine program, which has become a model for other nations, is a testament to the potential of public sector empowerment in health initiatives.

Despite the challenges posed , Shahul remains optimistic about the future of immunization in India. He calls for a collaborative approach that brings together scientists, policymakers, and healthcare professionals to create an inclusive framework for vaccine development and distribution. health over commercial interests, India can renew its commitment to eradicating preventable diseases and improving the health outcomes of its population.

In closing, Shahul’s insights serve as a critical reminder of the ethical considerations surrounding immunization and the need to honor the legacy of those who have dedicated their lives to vaccine research. As India continues to navigate the complexities of global health challenges, the voices advocating for a balanced and equitable vaccine approach must not be silenced.

Related News